239 related articles for article (PubMed ID: 36460795)
1. Sequential low-dose CT thorax scans to determine invasive pulmonary fungal infection incidence after allogeneic hematopoietic cell transplantation.
Enger K; Tonnar X; Kotter E; Bertz H
Ann Hematol; 2023 Feb; 102(2):413-420. PubMed ID: 36460795
[TBL] [Abstract][Full Text] [Related]
2. Epidemiology, management, and outcome of invasive fungal disease in patients undergoing hematopoietic stem cell transplantation in China: a multicenter prospective observational study.
Sun Y; Meng F; Han M; Zhang X; Yu L; Huang H; Wu D; Ren H; Wang C; Shen Z; Ji Y; Huang X
Biol Blood Marrow Transplant; 2015 Jun; 21(6):1117-26. PubMed ID: 25840339
[TBL] [Abstract][Full Text] [Related]
3. Management of Invasive Fungal Infections in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: The Turin Experience.
Busca A; Cinatti N; Gill J; Passera R; Dellacasa CM; Giaccone L; Dogliotti I; Manetta S; Corcione S; De Rosa FG
Front Cell Infect Microbiol; 2021; 11():805514. PubMed ID: 35071052
[TBL] [Abstract][Full Text] [Related]
4. Incidence and risk factors of post-engraftment invasive fungal disease in adult allogeneic hematopoietic stem cell transplant recipients receiving oral azoles prophylaxis.
Montesinos P; Rodríguez-Veiga R; Boluda B; Martínez-Cuadrón D; Cano I; Lancharro A; Sanz J; Arilla MJ; López-Chuliá F; Navarro I; Lorenzo I; Salavert M; Pemán J; Calvillo P; Martínez J; Carpio N; Jarque I; Sanz GF; Sanz MA
Bone Marrow Transplant; 2015 Nov; 50(11):1465-72. PubMed ID: 26281032
[TBL] [Abstract][Full Text] [Related]
5. Posaconazole oral suspension for secondary antifungal prophylaxis in allogeneic stem cell transplantation recipients: a retrospective study.
Ye P; Pei R; Hu Y; Chen D; Li S; Cao J; Li F; Wu M; Fang Y; Lu Y
BMC Infect Dis; 2022 May; 22(1):465. PubMed ID: 35570276
[TBL] [Abstract][Full Text] [Related]
6. Antifungal prophylaxis with fluconazole in allogeneic stem cell transplantation recipients who had prior invasive aspergillosis with subsequent complete resolution by computed tomography.
Akahoshi Y; Kimura SI; Gomyo A; Hayakawa J; Tamaki M; Harada N; Kusuda M; Kameda K; Ugai T; Wada H; Ishihara Y; Kawamura K; Sakamoto K; Sato M; Terasako-Saito K; Kikuchi M; Nakasone H; Kako S; Kanda Y
Infect Dis (Lond); 2018 Apr; 50(4):280-288. PubMed ID: 29087731
[TBL] [Abstract][Full Text] [Related]
7. Incidence and characteristics of invasive fungal diseases in allogeneic hematopoietic stem cell transplant recipients: a retrospective cohort study.
Harrison N; Mitterbauer M; Tobudic S; Kalhs P; Rabitsch W; Greinix H; Burgmann H; Willinger B; Presterl E; Forstner C
BMC Infect Dis; 2015 Dec; 15():584. PubMed ID: 26715563
[TBL] [Abstract][Full Text] [Related]
8. [Clinical investigation of reduced-dose voriconazole on primary prevention in invasive fungal disease after allogeneic hematopoietic stem cell transplantation].
Qiu Z; Ren H; Cen X; Ou J; Xu W; Wang M; Wang L; Dong Y; Li Y; Liu W; Sun Y; Liang Z; Wang Q
Zhonghua Xue Ye Xue Za Zhi; 2014 Jul; 35(7):577-80. PubMed ID: 25052595
[TBL] [Abstract][Full Text] [Related]
9. Decreased invasive fungal disease but no impact on overall survival by posaconazole compared to fluconazole prophylaxis: a retrospective cohort study in patients receiving induction therapy for acute myeloid leukaemia/myelodysplastic syndromes.
Dahlén T; Kalin M; Cederlund K; Nordlander A; Björkholm M; Ljungman P; Blennow O
Eur J Haematol; 2016 Feb; 96(2):175-80. PubMed ID: 25880378
[TBL] [Abstract][Full Text] [Related]
10. A Randomized Trial of Caspofungin vs Triazoles Prophylaxis for Invasive Fungal Disease in Pediatric Allogeneic Hematopoietic Cell Transplant.
Dvorak CC; Fisher BT; Esbenshade AJ; Nieder ML; Alexander S; Steinbach WJ; Dang H; Villaluna D; Chen L; Skeens M; Zaoutis TE; Sung L
J Pediatric Infect Dis Soc; 2021 Apr; 10(4):417-425. PubMed ID: 33136159
[TBL] [Abstract][Full Text] [Related]
11. Feasibility and effectiveness of posaconazole prophylaxis in combination with micafungin bridging for patients undergoing allogeneic stem cell transplantation: a 6-yr analysis from the cologne cohort for neutropenic patients.
Vehreschild MJ; von Bergwelt-Baildon M; Tran L; Shimabukuro-Vornhagen A; Wisplinghoff H; Bangard C; Cornely OA; Vehreschild JJ
Eur J Haematol; 2014 Nov; 93(5):400-6. PubMed ID: 24798021
[TBL] [Abstract][Full Text] [Related]
12. Breakthrough invasive fungal disease in patients receiving posaconazole primary prophylaxis: a 4-year study.
Lerolle N; Raffoux E; Socie G; Touratier S; Sauvageon H; Porcher R; Bretagne S; Bergeron A; Azoulay E; Molina JM; Lafaurie M
Clin Microbiol Infect; 2014 Nov; 20(11):O952-9. PubMed ID: 24861577
[TBL] [Abstract][Full Text] [Related]
13. Clinical efficacy and safety of primary antifungal prophylaxis with posaconazole versus fluconazole in allogeneic blood hematopoietic stem cell transplantation recipients-A retrospective analysis of a single medical center in Taiwan.
Wang CH; Kan LP; Lin HA; Chang FY; Wang NC; Lin TY; Chao TY; Kao WY; Ho CL; Chen YC; Dai MS; Chang PY; Wu YY; Lin JC
J Microbiol Immunol Infect; 2016 Aug; 49(4):531-8. PubMed ID: 25440977
[TBL] [Abstract][Full Text] [Related]
14. Clinical performance of metagenomic next-generation sequencing for diagnosis of invasive fungal disease after hematopoietic cell transplant.
Zhang X; Zhang L; Li Y; Wang N; Zhang Y
Front Cell Infect Microbiol; 2024; 14():1210857. PubMed ID: 38590441
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of posaconazole tablets versus fluconazole as prophylaxis for invasive fungal diseases in patients with graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
Grau S; Cámara R; Jurado M; Sanz J; Aragón B; Gozalbo I
Eur J Health Econ; 2018 May; 19(4):627-636. PubMed ID: 28569350
[TBL] [Abstract][Full Text] [Related]
16. Invasive Fungal Disease Among Pediatric and Adolescent Patients Undergoing Itraconazole Prophylaxis After Hematopoietic Stem Cell Transplantation.
Itsaradisaikul S; Pakakasama S; Boonsathorn S; Techasaensiri C; Rattanasiri S; Apiwattanakul N
Transplant Proc; 2021; 53(6):2021-2028. PubMed ID: 33994183
[TBL] [Abstract][Full Text] [Related]
17. Impact of neutropenia evaluated in terms of the D-index on invasive fungal disease while on empiric or preemptive antifungal treatment strategy in the early phase after allogeneic hematopoietic stem cell transplantation.
Kimura SI; Nakamura Y; Kawamura M; Takeshita J; Kawamura S; Yoshino N; Misaki Y; Yoshimura K; Matsumi S; Gomyo A; Akahoshi Y; Tamaki M; Kusuda M; Kameda K; Wada H; Sato M; Terasako-Saito K; Tanihara A; Nakasone H; Kako S; Kanda Y
Transpl Infect Dis; 2020 Dec; 22(6):e13409. PubMed ID: 32654234
[TBL] [Abstract][Full Text] [Related]
18. Real-world assessment of the effectiveness of posaconazole for the prophylaxis and treatment of invasive fungal infections in hematological patients: A retrospective observational study.
Chen X; Wang J; Wang S; Jin J; Li J; Gao S; Li J; Li J; Liu Q; Hu Y; Lin D; Sun Z; Yang J; Hu J; Wu X; Huang X; Shao Z; Deng Q; Wang C; Liu L; Chen H; Wang J; Wei X; Shen J; Zhang X; Wu D
Medicine (Baltimore); 2021 Jul; 100(30):e26772. PubMed ID: 34397725
[TBL] [Abstract][Full Text] [Related]
19. A prospective feasibility study of primary prophylaxis against invasive fungal disease with voriconazole following umbilical cord blood transplantation with fludarabine-based conditioning.
Takagi S; Araoka H; Uchida N; Uchida Y; Kaji D; Ota H; Nishida A; Ishiwata K; Tsuji M; Yamamoto H; Ito T; Matsuno N; Yamamoto G; Asano-Mori Y; Hayashi M; Izutsu K; Masuoka K; Wake A; Makino S; Yoneyama A; Taniguchi S
Int J Hematol; 2014; 99(5):652-8. PubMed ID: 24664791
[TBL] [Abstract][Full Text] [Related]
20. Low incidence of invasive fungal disease following CD19 chimeric antigen receptor T-cell therapy for non-Hodgkin lymphoma.
Little JS; Aleissa MM; Beluch K; Gonzalez-Bocco IH; Marty FM; Manne-Goehler J; Koo S; Hammond SP; Jacobson CA
Blood Adv; 2022 Aug; 6(16):4821-4830. PubMed ID: 35802461
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
